These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36468725)

  • 1. Nonavalent human papillomavirus vaccine for cutaneous warts: a retrospective study.
    Shin MK; Seo JI
    Eur J Dermatol; 2022 Sep; 32(5):642-643. PubMed ID: 36468725
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of nonavalent human papillomavirus vaccine for recalcitrant warts.
    Dianzani C; Neagu N; Venuti A; Coscarella G; DE Franciscis B; Montini F; Zalaudek I; Conforti C
    Ital J Dermatol Venerol; 2023 Feb; 158(1):67-68. PubMed ID: 36939508
    [No Abstract]   [Full Text] [Related]  

  • 3. HPV Vaccine for Treatment of Recalcitrant Cutaneous Warts in Adults: A Retrospective Cohort Study.
    Waldman A; Whiting D; Rani M; Alam M
    Dermatol Surg; 2019 Dec; 45(12):1739-1741. PubMed ID: 31765341
    [No Abstract]   [Full Text] [Related]  

  • 4. Nonavalent human papilloma virus vaccine for the treatment of multiple recalcitrant warts: An open-label study.
    Shin JO; Son JH; Lee J; Kim HS; Ko HC; Kim BS; Kim MB; Shin K
    J Am Acad Dermatol; 2022 Apr; 86(4):940-941. PubMed ID: 33785384
    [No Abstract]   [Full Text] [Related]  

  • 5. Nonavalent human papillomavirus vaccination as alternative treatment for genital warts.
    Bossart S; Gabutti MP; Seyed Jafari SM; Hunger RE
    Dermatol Ther; 2020 Jul; 33(4):e13771. PubMed ID: 32500585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Quadrivalent Human Papillomavirus Vaccine in Recalcitrant Non-genital Warts: A Retrospective Study.
    Kuan LY; Chua SH; Pan JY; Yew YW; Tan WP
    Ann Acad Med Singap; 2020 Oct; 49(10):749-755. PubMed ID: 33283838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recalcitrant cutaneous warts treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, and 18) in a developmentally delayed, 31-year-old white man.
    Venugopal SS; Murrell DF
    Arch Dermatol; 2010 May; 146(5):475-7. PubMed ID: 20479293
    [No Abstract]   [Full Text] [Related]  

  • 8. Human papilloma virus vaccine for palmoplantar warts: A retrospective study of 18 patients.
    Merio L; Chanal J; Jachiet M; Pourcher V; Arnault JP; Jouhet C; Milpied-Homsi B; Bourgault-Villada I; Aubin F; Caux F; Fouéré S; Vicaut E; Beylot-Barry M; Chosidow O;
    J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):e223-e225. PubMed ID: 35972053
    [No Abstract]   [Full Text] [Related]  

  • 9. Clearance of recalcitrant warts in a pediatric patient following administration of the nine-valent human papillomavirus vaccine.
    Kost Y; Zhu TH; Blasiak RC
    Pediatr Dermatol; 2020 Jul; 37(4):748-749. PubMed ID: 32173894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.
    Chou HH; Chang SC; Sukarom I; Saxena K; Pavelyev A; Wu YH; Chang CJ
    Value Health Reg Issues; 2022 Nov; 32():79-87. PubMed ID: 36116338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clearance of genital warts in a pediatric patient following administration of the nonavalent human papillomavirus vaccine.
    Couselo-Rodríguez C; Pérez-Feal P; Alarcón-Pérez CE; Bou-Boluda L; Baselga E
    Int J Dermatol; 2021 Sep; 60(9):e377-e379. PubMed ID: 33825183
    [No Abstract]   [Full Text] [Related]  

  • 12. Quadrivalent human papilloma virus vaccine for the treatment of multiple warts: a retrospective analysis of 30 patients.
    Yang MY; Son JH; Kim GW; Kim HS; Ko HC; Kim MB; Lim KM; Kim BS
    J Dermatolog Treat; 2019 Jun; 30(4):405-409. PubMed ID: 30232912
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of Difficult-to-Treat Warts: Traditional and New Approaches.
    Friedman PC
    Am J Clin Dermatol; 2021 May; 22(3):379-394. PubMed ID: 33432476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
    Tay SK; Hsu TY; Pavelyev A; Walia A; Kulkarni AS
    BJOG; 2018 Mar; 125(4):478-486. PubMed ID: 29266694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon.
    Chatterjee A
    Expert Rev Vaccines; 2014 Nov; 13(11):1279-90. PubMed ID: 25256262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clearance of recalcitrant warts in a patient with idiopathic immune deficiency following administration of the quadrivalent human papillomavirus vaccine.
    Smith SP; Baxendale HE; Sterling JC
    Clin Exp Dermatol; 2017 Apr; 42(3):306-308. PubMed ID: 28070898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of the Human Papillomavirus Vaccination in Management of HPV-associated Cutaneous Lesions.
    Gay J; Johnson N; Kavuru V; Phillips M
    Skin Therapy Lett; 2021 Mar; 26(2):6-8. PubMed ID: 33769773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined bivalent human papillomavirus vaccine and Candida antigen versus Candida antigen alone in the treatment of recalcitrant warts.
    Marei A; Nofal A; Alakad R; Abdel-Hady A
    J Cosmet Dermatol; 2020 Mar; 19(3):758-762. PubMed ID: 31328869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonavalent Human Papillomavirus Vaccination as a Treatment for Skin Warts in Immunosuppressed Adults: A Case Series.
    Bossart S; Imstepf V; Hunger RE; Seyed Jafari SM
    Acta Derm Venereol; 2020 Mar; 100(6):adv00078. PubMed ID: 32115668
    [No Abstract]   [Full Text] [Related]  

  • 20. Vaccines against human papillomavirus infections: protection against cancer, genital warts or both?
    Joura EA; Pils S
    Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S125-S127. PubMed ID: 28034371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.